Skip to main content
Clinical Trials/NCT00895700
NCT00895700
Unknown
Not Applicable

WEB-based Distress Management Program for Implantable CARdioverter dEfibrillator Patients (WEBCARE) Trial

Tilburg University6 sites in 1 country350 target enrollmentMarch 2010

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Heart Diseases
Sponsor
Tilburg University
Enrollment
350
Locations
6
Primary Endpoint
Anxiety
Last Updated
13 years ago

Overview

Brief Summary

The implantable cardioverter defibrillator (ICD) is generally well-accepted by patients, but a subgroup experiences increased anxiety and poor quality of life. A web-based behavioral intervention may comprise a novel approach to reduce anxiety and enhance well-being in ICD patients, which may be equally effective and have advantages over more traditional forms of therapy, due to its low-threshold accessibility via the internet.

The purpose of this study is to determine whether patients receiving a behavioral intervention via the internet experience less anxiety and device concerns and improved quality of life compared to patients receiving usual care.

Registry
clinicaltrials.gov
Start Date
March 2010
End Date
February 2014
Last Updated
13 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Tilburg University
Responsible Party
Principal Investigator
Principal Investigator

Dr. SS Pedersen

Professor of cardiac psychology

Tilburg University

Eligibility Criteria

Inclusion Criteria

  • patients implanted with a cardioverter-defibrillator (ICD)
  • between 18-75 years of age
  • speaking and understanding Dutch
  • with access to the internet and ability to use the internet
  • providing written informed consent

Exclusion Criteria

  • a life expectancy less than 1 year
  • a history of psychiatric illness other than affective/anxiety disorders
  • on the waiting list for heart transplantation
  • with insufficient knowledge of the Dutch language

Outcomes

Primary Outcomes

Anxiety

Time Frame: 52 weeks

Anxiet

Time Frame: 26 weeks

Secondary Outcomes

  • Cortisol awakening response(52 weeks)

Study Sites (6)

Loading locations...

Similar Trials